XENEN Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Azetukalner Regulatory ProgressThe NDA submission converts positive focal-seizure trial results into a formal regulatory opportunity and establishes a potential path toward commercialization. If approved, azetukalner could provide Xenon with its first major product revenue stream and reduce dependence on development-stage funding.
Strong Liquidity And RunwayA substantial cash balance and multi-year runway allow Xenon to continue late-stage trials, prepare for a U.S. launch and advance its pipeline without immediate reliance on capital markets. This financial flexibility supports strategic execution through important regulatory and clinical milestones.
Durable Clinical Efficacy SignalsLong-term seizure reduction and sustained seizure-freedom outcomes provide evidence that azetukalner's potential benefit may persist beyond short controlled-study periods. Durable efficacy can strengthen physician adoption, support differentiation and improve the product's commercial opportunity if safety and approval remain favorable.
Bears Say
Severe Cash BurnThe scale and worsening trend of operating cash outflows show that Xenon is not yet generating cash from its business. Continued spending on trials, regulatory work and commercialization will consume liquidity, making future profitability and disciplined capital allocation important despite the current runway.
No Meaningful Current RevenueXenon remains highly dependent on successful clinical development and future approval because it has no meaningful trailing revenue base. Until a product reaches the market and generates recurring sales, the company lacks operating self-funding and remains exposed to development, regulatory and launch execution risk.
Psychiatry Trial Safety PauseThe enrollment pause introduces a structural setback to Xenon's neuropsychiatry pipeline by requiring safety evaluation and possible dosing modifications. It may delay data and development timelines, while the newly observed events could affect tolerability perceptions and the addressable opportunity for these indications.
Xenon News
XENEN FAQ
What was Xenon’s price range in the past 12 months?
Currently, no data Available
What is Xenon’s market cap?
Xenon’s market cap is $65.89B.
When is Xenon’s upcoming earnings report date?
Xenon’s upcoming earnings report date is Nov 11, 2026 which is in 39 days.
How were Xenon’s earnings last quarter?
Xenon released its earnings results on Aug 06, 2026. The company reported -$20.307 earnings per share for the quarter, beating the consensus estimate of -$20.874 by $0.567.
Is Xenon overvalued?
According to Wall Street analysts Xenon’s price is currently Undervalued.
Does Xenon pay dividends?
Xenon does not currently pay dividends.
What is Xenon’s EPS estimate?
Xenon’s EPS estimate is -20.73.
How many shares outstanding does Xenon have?
Xenon has 96,840,430 shares outstanding.
What happened to Xenon’s price movement after its last earnings report?
Xenon reported an EPS of -$20.307 in its last earnings report, beating expectations of -$20.874. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Xenon?
Currently, no hedge funds are holding shares in MX:XENEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Xenon Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$1,292.31 (― Upside)
$1,292.31 (― Upside)
Blogger Sentiment
Bullish
MX:XENEN Sentiment 71%
Sector Average 65%
Sector Average 65%
Insider Transactions
Bought Shares
Worth $18.8M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-0.48%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
92.17%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Xenon
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy. Another Kv7 potassium channel activator, XEN1101, is progressing through Phase II trials, targeting epilepsy and a range of other neurological conditions. The portfolio also includes NBI-921352, a selective inhibitor of the Nav1.6 sodium channel, which is undergoing Phase II clinical evaluation for SCN8A developmental and epileptic encephalopathy, alongside investigations for adult focal epilepsy and other potential indications. Furthermore, XEN007, a central nervous system-acting calcium channel modulator, is also in Phase II development. Beyond its internal development, Xenon Pharmaceuticals has established strategic collaborations. This includes a licensing and development agreement with Neurocrine Biosciences, Inc. focused on epilepsy treatments, and a partnership with Flexion Therapeutics, Inc. to advance PCRX301 (also known as XEN402), a Nav1.7 inhibitor, for post-operative pain management. Established in 1996, the company continues its mission to address significant unmet medical needs in neurology.
XENEN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple substantive positive developments: an imminent NDA submission supported by strong Phase 3 efficacy and compelling long-term open-label data, a healthy cash position ($1.2B) providing runway into 2029, advancing early-stage pain programs (including confirmed central exposure for Nav1.7) and active commercial build-out with encouraging HCP feedback. Key risks highlighted include the inherent uncertainty of regulatory review, pending readouts for MDD and pain PoC studies, ongoing payer/pricing discussions, common TEAEs that may affect tolerability at higher doses, and potential competition from future Kv7 entrants. On balance, the company's strengths (efficacy, safety dataset, cash runway, advancing pipeline and commercial preparations) outweigh the outstanding uncertainties and execution risks.View all MX:XENEN earnings summariesXENEN Stock 12 Month Forecast
Average Price Target
―ACADIA Pharmaceuticals
―
Stoke Therapeutics
―
Alto Neuroscience, Inc.
―
Rapport Therapeutics, Inc.
―
Seaport Therapeutics, Inc.
―